Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347559 | 1.00 | TSHR (0.57) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL14129276 | 0.94 | TSHR (0.52) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL95157 | 0.93 | TSHR (0.64) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL16606946 | 0.92 | TSHR (0.50) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL9418348 | 0.92 | TSHR (0.57) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12702903 | 0.92 | TSHR (0.53) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12629198 | 0.92 | TSHR (0.57) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| 1,4-Butanediol SCHEMBL2466524 | 0.91 | TSHR (0.48) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12277858 | 0.91 | TSHR (0.58) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL13230684 | 0.90 | TSHR (0.61) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125513-A1 | CURABLE RESIN COMPOSITIONS | ILLUMINA INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12559595-B2 | Curable resin compositions | ILLUMINA, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260042870-A1 | BINDER COMPOSITIONS AND USES THEREOF | KNAUF INSULATION SPRL (BE) | 2026-02-12 | — | — | US | claimed |
| WO-2025198684-A9 | BaTiO3 NANOCRYSTALS AND NANOCOMPOSITES | PIXELLIGENT TECHNOLOGIES LLC (US) | 2025-11-27 | — | — | WO | claimed |
| US-12466899-B2 | Binder compositions and uses thereof | KNAUF INSULATION SPRL (BE) | 2025-11-11 | — | — | US | claimed |
| US-20250319654-A1 | PROCESS FOR PRODUCING A THREE-DIMENSIONAL STRUCTURE | MATERIAS S R L (IT) | 2025-10-16 | — | — | US | claimed |
| EP-3872101-B1 | POLYMERIC PARTICLES | LIFE TECH AS (NO) | 2025-08-20 | — | — | EP | claimed |
| EP-3562511-B1 | RNAI THERAPIES FOR CEREBRAL ISCHEMIA | VIVIBABA INC (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250230334-A1 | SOLVENT-FREE FORMULATIONS AND NANOCOMPOSITES | PT SPE SUBCO LLC (US) | 2025-07-17 | — | — | US | claimed |
| EP-3455166-B1 | METHODS OF FORMING AEROGELS | QATAR FOUND EDUCATION SCIENCE & COMMUNITY DEV (QA) | 2025-06-25 | — | — | EP | claimed |
| WO-2022252071-A1 | A SYNTHETIC POLYMERIC POROUS MEDIUM WITH HIERARCHICAL MULTIPLE LAYER STRUCTURE, ITS DESIGN, SYNTHESIS, MODIFICATION, AND LIQUID CHROMATOGRAPHIC APPLICATIONS | SUZHOU SEPAX TECHNOLOGIES, INC (CN) | 2022-12-08 | — | — | WO | claimed |
| WO-2022253175-A1 | SYNTHETIC POLYMERIC POROUS MEDIUM WITH HIERARCHICAL MULTIPLE LAYER STRUCTURE, ITS DESIGN, SYNTHESIS, MODIFICATION, AND LIQUID CHROMATOGRAPHIC APPLICATIONS | SUZHOU SEPAX TECHNOLOGIES, INC (CN) | 2022-12-08 | — | — | WO | claimed |
| US-11517645-B2 | Bone-tendon graft biomaterial, use as a medical device and method of making same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-06 | — | — | US | claimed |
| EP-4089101-A1 | MIXED-MODE CHROMATOGRAPHY MEMBRANES | Merck Millipore Ltd (IE) | 2022-11-16 | — | — | EP | claimed |
| WO-2022204586-A1 | ZIRCONIA AND TITANIA FORMULATIONS AND NANOCOMPOSITES FOR NANOIMPRINT LITHOGRAPHY | PIXELLIGENT TECHNOLOGIES LLC (US) | 2022-09-29 | — | — | WO | claimed |
| US-20220306769-A1 | Binder Compositions and Uses Thereof | KNAUF INSULATION SPRL (BE) | 2022-09-29 | — | — | US | claimed |
| US-11325985-B2 | Binder compositions and uses thereof | KNAUF INSULATION SPRL (BE) | 2022-05-10 | — | — | US | claimed |
| US-11319246-B2 | Water-blocking systems including fibers coated with liquid radiation curable SAP compositions | COVESTRO (NETHERLANDS) B.V. (NL) | 2022-05-03 | — | — | US | claimed |
| US-11319390-B2 | Poly(ethylene glycol) methacrylate microgels, preparation method and uses | LVMH RECHERCHE (FR) | 2022-05-03 | — | — | US | claimed |
| EP-2961762-B1 | MIXED-MODE CHROMATOGRAPHY MEMBRANES | MERCK MILLIPORE LTD (IE) | 2022-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042870-A1 | BINDER COMPOSITIONS AND USES THEREOF | SMCHD1, VCL, FGB | TSHR 4450/4885ALDH1A1 1900/4885TP53 1718/4885 |
| US-12559595-B2 | Curable resin compositions | ACR, RARA, RAD51 | TSHR 2955/4885ALDH1A1 270/4885TP53 2238/4885 |
| US-20260125513-A1 | CURABLE RESIN COMPOSITIONS | RAD51, ACR, ACMSD | TSHR 3849/4885ALDH1A1 562/4885TP53 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.